GENinCode (GENI) Share Price, News & Analysis

Company Overview

GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test for familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test for diagnosis of hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.

Key Stats

• Today's Range: 3.80 to 3.93
• 50-Day Range: 3.61 to 5.28
• 52-Week Range: 3.34 to 10
• Volume: 382 shs
• Average Volume: 194,921 shs
• Market Capitalization: £6.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GENI Stock Analysis - Frequently Asked Questions

How have GENI shares performed this year?

GENinCode's stock was trading at GBX 5.25 at the start of the year. Since then, GENI shares have decreased by 25.2% and is now trading at GBX 3.93.
View the best growth stocks for 2024 here.

How do I buy shares of GENinCode?

Shares of GENI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of GENinCode own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GENinCode investors own include QUALCOMM (QCOM), Sound Energy (SOU), Zura Bio (ZURA), Capital One Financial (COF), Lincoln National (LNC), Ovid Therapeutics (OVID) and Plug Power (PLUG).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: Entertainment
• Current Symbol: LON:GENI
• CUSIP: N/A
• CIK: N/A
• Web: www.genincode.com
• Phone: 44 1865 955 847
• Fax: N/A
• Employees: 2,300
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-5,940,000.00
• Net Margins: -228.70%
• Pretax Margin: N/A
• Return on Equity: -156.92%
• Return on Assets: -63.99%

Debt

• Debt-to-Equity Ratio: 9.27
• Current Ratio: 2.60
• Quick Ratio: 15.89

Sales & Book Value

• Annual Sales: £2.60 million
• Price / Sales: 2.67
• Cash Flow: GBX 4.71 per share
• Price / Cash Flow: 0.83
• Book Value: GBX 2 per share
• Price / Book: 1.96

Miscellaneous

• Outstanding Shares: 176,960,000
• Free Float: N/A
• Market Cap: £6.95 million
• Optionable: Not Optionable
• Beta: 0.66